Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR VM Corman, O Landt, M Kaiser, R Molenkamp, A Meijer, DKW Chu, ... Eurosurveillance 25 (3), 2000045, 2020 | 8728 | 2020 |
Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant J Lopez Bernal, N Andrews, C Gower, E Gallagher, R Simmons, ... New England Journal of Medicine 385 (7), 585-594, 2021 | 3249 | 2021 |
Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard, E Gallagher, ... New England Journal of Medicine 386 (16), 1532-1546, 2022 | 2157 | 2022 |
Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study D Nepogodiev, A Bhangu, JC Glasbey, E Li, OM Omar, JFF Simoes, ... The Lancet 396 (10243), 27-38, 2020 | 1868 | 2020 |
Commentary: Middle east respiratory syndrome coronavirus (mers-cov): announcement of the coronavirus study group RJ De Groot, SC Baker, RS Baric, CS Brown, C Drosten, L Enjuanes, ... Journal of virology 87 (14), 7790-7792, 2013 | 1671 | 2013 |
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome T Kuiken, RAM Fouchier, M Schutten, GF Rimmelzwaan, ... The Lancet 362 (9380), 263-270, 2003 | 1325 | 2003 |
Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020 A Singanayagam, M Patel, A Charlett, JL Bernal, V Saliba, J Ellis, ... Eurosurveillance 25 (32), 2001483, 2020 | 1039 | 2020 |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 961 | 2022 |
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study E Miller, K Hoschler, P Hardelid, E Stanford, N Andrews, M Zambon The Lancet 375 (9720), 1100-1108, 2010 | 880 | 2010 |
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B. 1.617. 2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal … A Singanayagam, S Hakki, J Dunning, KJ Madon, MA Crone, A Koycheva, ... The lancet infectious diseases 22 (2), 183-195, 2022 | 843 | 2022 |
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 800 | 2021 |
Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 793 | 2021 |
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction VM Corman, I Eckerle, T Bleicker, A Zaki, O Landt, M Eschbach-Bludau, ... Eurosurveillance 17 (39), 2012 | 763 | 2012 |
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 706 | 2021 |
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study S de Lusignan, J Dorward, A Correa, N Jones, O Akinyemi, ... The Lancet Infectious Diseases 20 (9), 1034-1042, 2020 | 698 | 2020 |
Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012 A Bermingham, MA Chand, CS Brown, E Aarons, C Tong, C Langrish, ... Eurosurveillance 17 (40), 2012 | 643 | 2012 |
Unexpected receptor functional mimicry elucidates activation of coronavirus fusion AC Walls, X Xiong, YJ Park, MA Tortorici, J Snijder, J Quispe, E Cameroni, ... Cell 176 (5), 1026-1039. e15, 2019 | 636 | 2019 |
Duration of protection against mild and severe disease by Covid-19 vaccines N Andrews, E Tessier, J Stowe, C Gower, F Kirsebom, R Simmons, ... New England Journal of Medicine 386 (4), 340-350, 2022 | 611 | 2022 |
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study COVIDSurg Collaborative Anaesthesia 76 (6), 748-758, 2021 | 574* | 2021 |
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza KG Nicholson, AE Colegate, A Podda, I Stephenson, J Wood, E Ypma, ... The Lancet 357 (9272), 1937-1943, 2001 | 529 | 2001 |